OSTX Company Profile and Key Details

OSTX has shown mixed momentum, gaining 4.17% over the past week and -18.92% over the past quarter, though year-to-date performance is up 7.14%. Short-term trend indicators are bullishly aligned (SMA20 11.15%, SMA50 0.9%, SMA200 -18.99%). The stock’s 14-day RSI is 57.84 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.36% below its high and over 27.68% above its low. Average 10-day trading volume of 1.47 million shares is significantly above the 3-month average of 772.75 thousand, indicating heightened recent market interest.

OS Therapies Incorporated has 31.62 million shares outstanding. The public float is 20.95 million shares, elevated short interest at 1.25% of float. This equals 348.36 thousand shares. The short ratio is 0.51 days. Institutional investors hold 2.77% of the float. Insiders own 31.15%.

OS Therapies Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.01. This means the shares are trading above this model’s fair value.

OS Therapies Incorporated generated EPS of -$0.82 over the past year. Five-year average earnings growth is 79.38%. Wall Street analysts project EPS growth of 43.35% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 22 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $20.00 to $7.00. The high target offers 1062.79% upside. The low target suggests 306.98% downside. The mean target is $18.95. This offers 1001.74% upside. OS Therapies Incorporated earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 18, 2026, missed forecasts by 58.82%. The prior quarter beat by 168.38%. Over the last six quarters, Apple has recorded several small beats. These include 71.43% in March 31, 2025.

OS Therapies Incorporated (AMEX:OSTX) closed at $1.72 USD, gaining $0.26 (17.81%) from the previous close of $1.46. The stock is currently mid-range between its 52-week high and low $1.15 and $2.57. With a market capitalization of about $76.61 million, OS Therapies Incorporated is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.83). Key stats such as the average daily volume over the past year has been around 813.35 thousand shares, trading with heavier-than-usual volume. Headquartered in Grasonville, MD, OS Therapies Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul A. Romness, the company employs approximately 5 people and listed since August 01, 2024. OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

OS Therapies Incorporated trades at a P/E ratio of -1.55, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -5.93 indicating negative book value, which may reflect financial stress. The P/FCF stands at -4.72, also below market averages.

OS Therapies Incorporated (AMEX:OSTX) shares are flat 7.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows OS Therapies Incorporated trading at a premium to the broader market with a P/E of -1.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.25, suggesting 1019.19% upside. Our AI forecast model points to short-term weakness (-11.63% over two weeks), a medium-term fall (-88.95% over three months), and a longer-term gain (219.77% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that OS Therapies Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.63%, with price expected at $1.52 by July 22, 2026, within a range of $1.37 to $1.66 3-Month Outlook: Projected fall of -88.95%, reaching $0.19 by October 06, 2026, with a range of $0.08 to $0.28. 1-Year Outlook: Projected gain of 219.77%, with price at $5.50 by July 08, 2027, within a range of $0.49 to $6.52.